Biio.

A wider range of joint movement is not, in itself, a clinical problem. Many people are hypermobile and well.

The picture changes when the body has to do more work than it should to stay still, stay upright, stay loaded. Connective tissue gives less passive support. Muscles, ligaments, and the autonomic system pick up the difference.

What looks like weakness from the outside is often a body spending more energy on ordinary positions than another body would.

biio. reads hypermobility as a load pattern, not as a fragility label.

Complex invisible illness in young people is often missed because it doesn't look the way medicine expects.

A teenager who faints at school is not always anxious. A child who cannot tolerate the school uniform may not be difficult. Fatigue that doesn't lift after rest, joint pain disproportionate to activity, gut symptoms without a clear allergy — these are not phases to wait out. They are signals worth reading carefully.

The conditions that appear most often in young people with complex invisible illness — hypermobility, POTS and dysautonomia, post-viral patterns, ADHD and autism, mast cell activation — rarely arrive one at a time. The child with connective tissue instability may also have autonomic symptoms and sensory processing differences. The adolescent recovering from a viral illness may have post-exertional fatigue intersecting with an unrecognised neurodevelopmental profile. These connections change the clinical picture.

biio. has built a dedicated Child & Adolescent Pathway for ages 8 to 18. The care brings together paediatric medicine, physiotherapy, psychology, dietetics, exercise physiology, and genetic counselling — in a shared record that allows clinical reasoning to travel, not fragment.

Minimal wait-time. Australia-wide. Book Online or Refer Today.

MCAS and EDS are frequently found together. The biological relationship between them is becoming clearer.

Mast cells are embedded in connective tissue throughout the body. Their behaviour is partly regulated by the structural environment they sit in. In EDS and HSD, where the extracellular matrix is disorganised, the mechanical signals that normally moderate mast cell reactivity may be disrupted — leaving them more prone to inappropriate activation.

The relationship runs in both directions. Mast-cell-derived tryptase can directly degrade connective tissue proteins, potentially worsening the structural fragility that made mast cells more reactive in the first place. Each can amplify the other.

biio. reads the relationship between conditions, not only the conditions in isolation.

References: The EDS Clinic (2024). | Weinstock LB et al. (2024). ScienceDirect.

What being disbelieved for 15 to 22 years does to a body and a life is measurable.

The standardised mortality ratio for su***de in ME/CFS is 6.85 — roughly seven times the matched general population (Roberts et al., The Lancet, 2016).

In a controlled study of POTS patients, 48% screened as high su***de risk, against 18% of controls. 16% had attempted (Pederson & Brook, 2017).

In a Karolinska study of 1,771 Swedes with EDS, su***de-attempt risk was 2.1 times the general population (Cederlöf et al., 2016).

These are not numbers about the illnesses themselves. They are numbers about what happens to people when the system meets a real, measurable condition with disbelief, for years.

If you are struggling, Lifeline is available 24 hours a day on 13 11 14.

A standard outpatient physiotherapy appointment in Australia runs 20 minutes.

biio.'s physiotherapy assessment for complex hereditary connective tissue presentations runs 90 to 120 minutes. It is built specifically for the clinical question being asked.

You cannot do a multi-system symptom assessment, family history review, Beighton, hEDS diagnostic criteria checklist, pain and sensitisation history, orthostatic tolerance test and a connective-tissue skin examination in 20 minutes.

You can do all of it in 90 to 120 — when the appointment is designed for the work.

The difference is not in the clinician. The difference is in the time the system gives the clinician to do the work properly.

In a 2025 global cohort of nearly 3,400 people with hypermobile Ehlers-Danlos syndrome, 49 % self-reported at least one neurodivergent diagnosis. Most commonly ADHD, autism, or OCD.

The autism–hypermobility–dysautonomia cluster is real, female-dominated, and structurally under-recognised.

The clinical question is rarely "is this patient hypermobile, or autistic, or dysautonomic?" It is, often, all three at once.

A pathway designed around one of these in isolation will keep producing the wait we already have.

Source: Daylor et al., 2025.

A reminder that complex invisible illness almost never travels alone.

The single-condition lens — see the patient through hEDS only, or POTS only, or MCAS only — is one of the reasons diagnostic delay for this group runs to a decade or more. Patients arrive with several diagnoses, none of which holds the whole picture.

Care designed around one of these conditions in isolation is care designed against the actual presentation.

Source: Bordoni et al., 2025.

biio. is three things working together. Remove any one and the model breaks.

Clinical capability without a shared method becomes a roster of specialists who don't talk.
Shared method without shared technology becomes a beautiful protocol that no team can actually run together.
Shared technology without clinical capability is a storage cupboard.

Our model is all three at once.

For thirty years, hypermobile Ehlers-Danlos syndrome was cited at a prevalence of 1 in 5,000.

The current best evidence — 27 years of Welsh GP and hospital records, 1.69 million people — puts it at 1 in 500.

That is a tenfold revision in how many people we are talking about. Translated to Australia: roughly 55,000 people already diagnosed. The symptomatic population — those with the condition but not yet recognised — is several multiples higher.

If your sense of how rare hEDS is was set in medical school, it is almost certainly out of date.

Source: Demmler et al., BMJ Open.

Many people arrive at biio. after years of summarising something complex into ten or fifteen minutes.

That compression has a cost.

Important details disappear. Timelines flatten. Symptoms that looked separate are not given enough room to show their relationship to one another.

The first appointment at biio. is designed differently. It gives the story enough space to be heard as a whole, so the pattern can begin to appear.

Not everything is solved in one appointment.

But the first appointment should not make the person smaller so the system can fit around them.